Sector
PharmaceuticalsOpen
₹363Prev. Close
₹366Turnover(Lac.)
₹115.11Day's High
₹370.1Day's Low
₹347.752 Week's High
₹380.852 Week's Low
₹210.1Book Value
₹128.84Face Value
₹10Mkt Cap (₹ Cr.)
795.14P/E
45.34EPS
7.99Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 26.55 | 19.04 | 17.12 | 15.62 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 235.87 | 154.39 | 110.42 | 82.84 |
Net Worth | 262.42 | 173.43 | 127.54 | 98.46 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 94.73 | 82.98 | 53.07 | 44.17 |
yoy growth (%) | 14.17 | 56.34 | 20.16 | 7.14 |
Raw materials | -51.11 | -43.04 | -27.99 | -22.28 |
As % of sales | 53.95 | 51.87 | 52.75 | 50.45 |
Employee costs | -13.25 | -12.12 | -6.83 | -5.94 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 13.24 | 12.22 | 6.12 | 4.82 |
Depreciation | -8.05 | -7.07 | -4.4 | -3.38 |
Tax paid | -2.55 | -2.6 | -2.29 | -1.44 |
Working capital | -6.96 | -4.37 | -1.06 | 8.98 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.17 | 56.34 | 20.16 | 7.14 |
Op profit growth | 15.68 | 55.25 | 23.85 | 21.84 |
EBIT growth | 8.59 | 66.22 | 16.01 | 29.13 |
Net profit growth | 11.11 | 152.25 | 12.91 | 52.31 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 177.58 | 153.35 | 133.36 | 128.23 | 94.74 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 177.58 | 153.35 | 133.36 | 128.23 | 94.74 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 1.31 | 3.18 | 4.67 | 2.17 | 1.18 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sanjay S Shah.
Joint Managing Director
Aarsh S Shah
Independent Non Exe. Director
Shailesh B Patel
Independent Non Exe. Director
Prashant C Srivastav
Independent Non Exe. Director
Hemendrakumar C Shah
Non Executive Director
Ritaben S Shah
Whole Time Director
Sunil Marathe
Non Executive Director
Visalakshi Chandramouli
Independent Non Exe. Director
JIGNESH MUKUNDBHAI PARIKH
Independent Non Exe. Director
Khyati B. Shah
Company Sec. & Compli. Officer
Bharat Soni
10/13 Nr MN Desai Petrol Pump,
Sarkhej Bavla Highway,
Gujarat - 382213
Tel: 91-2717-250477
Website: http://www.sakarhealthcare.com
Email: [email protected]
5th Floor 506 to 508,
ABC-I Off C G Road, Navrangpura,
Ahmedabad-380009
Tel: 91-79-26465179
Website: https://in.mpms.mufg.com/
Email: [email protected]
Summary
Sakar Healthcare Limited was incorporated as a Private Limited Company under the name Sakar Healthcare Private Limited on 26th March 2004. Subsequently, the Company was converted into Public Limited C...
Read More
Reports by Sakar Healthcare Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.